There’s a newly revised FDA warning about Citalopram based on rethinking the indication for treating psychiatric illness, the benefits of which might outweigh the relatively small risk for cardiac arrhythmia in some patients who lack the criteria which might lead doctors to avoid prescribing the antidepressant altogether. The new warning, excerpted from the article in HealthDay (see link below):
- “Celexa should not be used at doses greater than 40 milligrams (mg).
- Celexa is not recommended for use in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent heart attack, or uncompensated heart failure.
- Use of the Celexa is also not recommended in patients who are taking other drugs that prolong the QT interval, a measure of a heart’s electrical activity.
- The maximum recommended dose of Celexa is 20 mg per day for patients with liver impairment, patients who are older than 60, patients who are CYP 2C19 poor metabolizers, or patients who are also taking cimetidine (Tagamet) or another CYP 2C19 inhibitor. All of these factors lead to increased blood levels of Celexa, increasing the risk of QT interval prolongation and Torsade de Pointes, the FDA said.”
Other links to the story:
One of my posts with related information at short link http://wp.me/p1glcu-16E.